Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 16/20 | 0.50 |
| ▸ | CNR1 | P21554 | 10/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2773749 | 0.88 | CNR2 (0.49) | CNR2CNR1NPC1RAB9A | |
| SCHEMBL13157524 | 0.84 | CNR2 (0.43) | CNR2CNR1 | |
| SCHEMBL2775152 | 0.84 | CNR2 (0.43) | CNR2CNR1 | |
| SCHEMBL2772363 | 0.83 | CNR2 (0.52) | CNR2CNR1 | |
| SCHEMBL2774194 | 0.81 | L3MBTL1 (0.39) | CNR2CNR1 | |
| SCHEMBL2773251 | 0.78 | KDM4E (0.43) | CNR2CNR1 | |
| SCHEMBL2776275 | 0.74 | CNR2 (0.52) | CNR2CNR1 | |
| SCHEMBL13156806 | 0.73 | CNR2 (0.55) | CNR2CNR1 | |
| SCHEMBL13175893 | 0.73 | CNR2 (0.53) | CNR2CNR1 | |
| SCHEMBL1432870 | 0.72 | CNR2 (0.67) | CNR2CNR1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2230243-A1 | Pharmaceutical compounds | Neuroscienze Pharmaness S.C. A R.L. (IT) | 2010-09-22 | — | — | EP | disclosed |
| EP-2230243-A1 | Pharmaceutical compounds | Neuroscienze Pharmaness S.C. A R.L. (IT) | 2010-09-22 | — | — | EP | disclosed |
| US-20100215759-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C.A.R.L. (IT) | 2010-08-26 | — | — | US | disclosed |
| US-20100215759-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C.A.R.L. (IT) | 2010-08-26 | — | — | US | disclosed |
| US-20100215759-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C.A.R.L. (IT) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100215759-A1 | PHARMACEUTICAL COMPOUNDS | CNR2, CNR1, OPRK1 | CNR2 1/4885CNR1 2/4885NPC1 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.